Loading…
← CockpitCompetitor Analysis › 6929.HK OrbusNeich Medical Group Holdings LimitedOpen in the cockpit ↗

OrbusNeich Medical Group Holdings Limited6929.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum strong 66
Mkt cap
$394M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$23,546
20-day average traded
Fwd P/E
8.4×
forward earnings
ROIC−WACC
+9.8 pp
WACC 6.6%
Hurdle
-33 pp
Req g minus delivered
Next earnings
113 days
11 Mar 2027
Close · HKDHK$3.83
1D+1.2%
1W+3.4%
1M+0.7%
3M-3.2%
6M-15.0%
YTD+5.7%
1Y-16.1%
ATR %2.7%
52w lowhigh21.5% off high

What OrbusNeich Medical does

Employees: 1,477

OrbusNeich Medical at a glance

Size OrbusNeich Medical (6929.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $394M, the 816th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.83 on 18 Nov 2026.

Performance Over six months the shares fell 15.0%, against -22.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 16.2% over the last twelve months (peer median +13.9%); the operating margin is 23.0% (peer median 4.2%).

Valuation It trades at 8.4× forward earnings against a peer median of 18.2× (2nd cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -33 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.8 points above its cost of capital (6.6% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 20266929.HK 85Peer median 76
Six months, rebased to 100: OrbusNeich Medical against the median of its 20 peers (local-currency closes).

OrbusNeich Medical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.53BHK$1.41BHK$1.28BHK$1.20BHK$1.07B
Revenue growth—+10%+6%+12%—
Gross profitHK$1.05BHK$936MHK$875MHK$821MHK$711M
EBITDAHK$407MHK$350MHK$310MHK$324MHK$258M
Net incomeHK$341MHK$327MHK$310MHK$353MHK$145M
Free cash flowHK$193MHK$106MHK$122MHK$168MHK$165M
Capital expenditureHK$199MHK$143MHK$87.9MHK$58.6MHK$26.1M
Total debtn/aHK$30.5MHK$32.6MHK$58.3MHK$31.4M

Quarterly statements and history in the cockpit →

OrbusNeich Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%MASS458870CERS300238002022473604183067489877BWAY301097CVSBS16096929.HK6-month return →1-month return →
Up and to the right = strong over both horizons. OrbusNeich Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%10×20×30×458870688133688358041830605186300562BWAY300515SBS6929.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OrbusNeich Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%MASS4588704736688358041830BWAY3005156929.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. OrbusNeich Medical is the large dot.

OrbusNeich Medical competitors and peer comparison

How OrbusNeich Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OrbusNeich Medical against its 20 peers (data as of 18 Nov 2026)
Measure6929.HKPeer medianRank in peer set
1-month return+0.7%-11.5%4th highest of 21
6-month return-15.0%-22.4%8th highest of 20
Distance from 52-week high-21.5%-45.3%3rd highest of 21
Revenue growth (TTM)+16.2%+13.9%9th highest of 21
Operating margin23.0%4.2%4th highest of 21
Forward P/E8.4×18.2×2nd cheapest of 10
Growth the price implies (Req g, 7 yrs)-17.6%-0.1%least demanding of 12
Growth delivered (Del g)+15.4%+15.9%5th lowest of 12
Hurdle (Req g minus delivered)-33.1 pp-1.0 pp3rd least demanding of 12
ROIC minus cost of capital+9.8 pp-2.1 pp8th highest of 20
EV / EBITDA3.9×11.6×cheapest of 9
Net debt / EBITDA-3.7×-1.2×4th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%8.4×-17.6%+15.4%
908 Devices MASSUnited States$396M+36%+14%-33%n/a41.7%+15.9%
SEERS 458870.KSSouth Korea$392M-70%+174%37%15.2×-6.3%+247.0%
Cerus CERSUnited States$392M-28%+14%-12%n/an/an/a
Guanhao Biotech 300238.SZChina$397M-26%-12%3%n/an/an/a
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%n/an/an/a
Taidoc Technology 4736.TWTaiwan$387M0%0%19%n/a-9.5%-6.6%
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%8.4×n/an/a
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%19.8×9.6%+5.6%
InBody 041830.KSSouth Korea$380M-13%+22%22%11.3×-10.3%+16.9%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%37.2×n/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%n/a17.1%+18.1%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%n/an/an/a
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%n/an/an/a
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
Hunan Sundy Science and Technology 300515.SZChina$425M-16%+10%27%13.2×-0.1%+15.6%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%

Questions

Which companies are OrbusNeich Medical's closest peers?
The cockpit's peer set: 908 Devices (MASS), SEERS (458870.KS), Cerus (CERS), Guanhao Biotech (300238.SZ), Shanghai Kehua Bio-Engineering (002022.SZ), Taidoc Technology (4736.TW), Shanghai Titan Scientific (688133.SS), Chison Medical Technologies (688358.SS).
Is OrbusNeich Medical expensive compared with its peers?
On forward p/e it trades at 8.4× against a peer median of 18.2×, 2nd cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -33 pp: the price already allows for a slowdown.
How has OrbusNeich Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -15.0% against -22.4% for the median peer; over one year -16.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.